Edition:
United States

Biomarin Pharmaceutical Inc (BMRN.OQ)

BMRN.OQ on NASDAQ Stock Exchange Global Select Market

99.93USD
3:48pm EDT
Change (% chg)

$0.42 (+0.42%)
Prev Close
$99.51
Open
$99.40
Day's High
$100.88
Day's Low
$98.54
Volume
263,611
Avg. Vol
447,056
52-wk High
$106.19
52-wk Low
$75.84

Latest Key Developments (Source: Significant Developments)

Biomarin Pharmaceutical Reports Q1 Loss Per Share Of $0.25
Wednesday, 25 Apr 2018 04:05pm EDT 

April 25 (Reuters) - Biomarin Pharmaceutical Inc ::BIOMARIN ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS.Q1 REVENUE $373.4 MILLION VERSUS I/B/E/S VIEW $348.7 MILLION.Q1 GAAP LOSS PER SHARE $0.25.SEES FY 2018 REVENUE ABOUT $1.5 BILLION.Q1 EARNINGS PER SHARE VIEW $-0.17 -- THOMSON REUTERS I/B/E/S.AS OF MARCH 31, 2018, BIOMARIN HAD CASH, CASH EQUIVALENTS AND INVESTMENTS TOTALING ABOUT $1.7 BILLION.  Full Article

BioMarin Q4 GAAP Loss Per Share $0.30
Thursday, 22 Feb 2018 04:05pm EST 

Feb 22 (Reuters) - BioMarin Pharmaceutical Inc ::BIOMARIN ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS.Q4 GAAP LOSS PER SHARE $0.30.QTRLY TOTAL REVENUES $358.3 MILLION VERSUS $300.1 MILLION.SEES 2018 TOTAL REVENUES $1,470 MILLION TO $1,530 MILLION.SEES 2018 GAAP NET LOSS OF $115 MILLION TO $165 MILLION.SEES 2018 NON-GAAP INCOME OF $100 MILLION TO $140 MILLION.Q4 REVENUE VIEW $351.6 MILLION -- THOMSON REUTERS I/B/E/S.FY2018 REVENUE VIEW $1.48 BILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Biomarin Receives Anticipated Notification Of PDUFA Extension For Pegvaliase Biologics License Application
Friday, 22 Dec 2017 08:30am EST 

Dec 22 (Reuters) - Biomarin Pharmaceutical Inc ::BIOMARIN RECEIVES ANTICIPATED NOTIFICATION OF PDUFA EXTENSION FOR PEGVALIASE BIOLOGICS LICENSE APPLICATION (BLA) TO MAY 28, 2018.BIOMARIN PHARMACEUTICAL INC - U.S. FDA WILL REQUIRE ADDITIONAL TIME TO COMPLETE ITS REVIEW OF BIOLOGICS LICENSE APPLICATION FOR PEGVALIASE.BIOMARIN PHARMACEUTICAL INC - ACTION GOAL DATE FOR PEGVALIASE BIOLOGICS LICENSE APPLICATION WILL BE MAY 25, 2018.  Full Article

Biomarin Sells Second Priority Review Voucher For $125 Mln
Monday, 27 Nov 2017 08:45am EST 

Nov 27 (Reuters) - Biomarin Pharmaceutical Inc ::BIOMARIN SELLS SECOND PRIORITY REVIEW VOUCHER FOR $125 MILLION.BIOMARIN PHARMACEUTICAL INC - ‍ENTERED AGREEMENT TO SELL RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER IT OBTAINED IN APRIL OF THIS YEAR​.BIOMARIN PHARMACEUTICAL - ‍SALE OF PRV WILL BE RECORDED AS A $125 MILLION GAIN ON SALE OF AN INTANGIBLE ASSET.BIOMARIN PHARMACEUTICAL INC - ‍NON-GAAP INCOME GUIDANCE FOR FULL-YEAR 2017 IS UNCHANGED AT $60 TO $80 MILLION​.BIOMARIN PHARMACEUTICAL INC- ‍FOR FULL YEAR 2017, GAAP NET LOSS GUIDANCE WILL BE REDUCED TO BETWEEN $10 MILLION AND $30 MILLION​.  Full Article

Biomarin reports Q3 loss $0.07/shr
Thursday, 26 Oct 2017 04:05pm EDT 

Oct 26 (Reuters) - Biomarin Pharmaceutical Inc :Biomarin announces third quarter 2017 financial results.Q3 GAAP loss per share $0.07.Q3 earnings per share view $-0.14 -- Thomson Reuters I/B/E/S.Sees FY 2017 revenue $1.29 billion to $1.32 billion.Q3 revenue $334.1 million versus I/B/E/S view $347.4 million.FY2017 revenue view $1.31 billion -- Thomson Reuters I/B/E/S.Biomarin Pharmaceutical Inc sees ‍ full-year non-GAAP income $60 million to $80 million ​.Biomarin Pharmaceutical Inc sees ‍full-year GAAP net loss $110 to $130​.  Full Article

FDA grants Breakthrough Therapy Designation for BioMarin's gene therapy for hemophilia A
Thursday, 26 Oct 2017 08:30am EDT 

Oct 26 (Reuters) - BioMarin Pharmaceutical Inc :FDA grants Breakthrough Therapy Designation for BioMarin's valoctocogene roxaparvovec (formerly BMN 270), an investigational gene therapy for hemophilia A.BioMarin Pharmaceutical Inc - ‍BioMarin expects to initiate enrollment of a global Phase 3 program before end of year​.  Full Article

Biomarin presents interim data of phase 1/2 study of BMN 250 for treatment of Sanfilippo B syndrome
Wednesday, 6 Sep 2017 11:00am EDT 

Sept 6 (Reuters) - Biomarin Pharmaceutical Inc :Biomarin presents interim data of phase 1/2 study of BMN 250 for treatment of Sanfilippo B syndrome (MPS IIIB) at 13th international congress of inborn errors of metabolism (ICIEM) 2017.Says ‍interim trial data indicates that ICV-administered bmn 250 was well-tolerated by Sanfilippo B patients​.  Full Article

FDA accepts Biomarin's Pegvaliase Biologics License Application
Tuesday, 29 Aug 2017 04:05pm EDT 

Aug 29 (Reuters) - Biomarin Pharmaceutical Inc :FDA accepts Biomarin's Pegvaliase Biologics License Application (bla) and grants priority review designation.Biomarin Pharmaceutical Inc - ‍PDUFA action date is February 28, 2018​.Biomarin Pharmaceutical Inc - ‍FDA has requested additional Chemistry, Manufacturing, and Controls (CMC) information for Pegvaliase​.Biomarin - ‍When additional information is submitted to FDA, it will be classified as major amendment and result in 3 month extension of PDUFA date​.Biomarin Pharmaceutical Inc - FDA has not informed company whether an advisory committee meeting to discuss pegvaliase​ application will be needed.  Full Article

BioMarin announces offering of $450 mln of 0.599 pct senior convertible notes
Monday, 7 Aug 2017 08:04pm EDT 

Aug 7 (Reuters) - BioMarin Pharmaceutical Inc -:BioMarin announces offering of $450 million of 0.599% senior subordinated convertible notes due 2024.BioMarin - to use majority of net proceeds to repay, repurchase or settle in cash some or all of co's 0.75% senior subordinated notes due in October 2018.  Full Article

Biomarin announces offering of $450 mln of senior subordinated convertible notes due 2024
Monday, 7 Aug 2017 04:01pm EDT 

Aug 7 (Reuters) - Biomarin Pharmaceutical Inc :Biomarin announces offering of $450 million of senior subordinated convertible notes due 2024.Biomarin- to use majority of proceeds from offering to repay, repurchase or settle in cash co's 0.75% senior subordinated convertible notes due in Oct 2018​.  Full Article

Photo

S&P, Dow fall as oil drop hurts energy; chipmakers boost Nasdaq

NEW YORK The S&P 500 and the Dow eased on Friday after a steep drop in oil prices pressured energy stocks, but losses were limited by gains in chipmakers and retail stocks.